Acumen Pharma to Unveil 2025 Results as Alzheimer's Drug Advances
Acumen Pharmaceuticals will report full-year 2025 financial results on March 26, 2026, as its lead Alzheimer's candidate progresses through Phase 2 trials.
HALOABOSPhase 2 clinical trialfinancial results